HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $5.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Terns Pharma (NASDAQ:TERN) and maintained a price target of $5.5.

April 30, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Terns Pharma maintains a Neutral rating and a $5.5 price target from HC Wainwright & Co.
The reiteration of a Neutral rating and maintenance of the price target suggests that HC Wainwright & Co. sees no significant short-term catalysts that would materially change the stock's valuation. This stability in analyst outlook is likely to have a neutral impact on TERN's stock price in the short term, as it does not alter the investment thesis.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100